mycetoma
neglect
tropic
diseas
endem
mani
tropic
subtrop
region
characteris
massiv
deform
disabl
fatal
untreat
earli
appropri
interleukin
il
newli
discov
cytokin
play
import
role
suppress
immun
system
howev
express
interleukin
patient
madurella
mycetomati
mycetomati
induc
eumycetoma
yet
explor
studi
aim
determin
level
famili
famili
group
patient
associ
cytokin
level
patient
demograph
characterist
present
casecontrol
studi
conduct
mycetoma
research
centr
soba
univers
hospit
univers
khartoum
sudan
includ
individu
divid
two
group
group
healthi
control
n
median
age
year
rang
year
group
ii
mycetoma
patient
n
patient
median
age
rang
year
cytokin
level
measur
sera
use
enzymelink
immunosorb
assay
elisa
signific
correl
level
lesion
size
diseas
durat
wherea
level
significantli
correl
analysi
risk
factor
higher
circulatori
level
patient
mycetoma
show
signific
neg
associ
cytokin
unit
increment
decreas
level
pgml
level
among
patient
durat
mycetoma
infect
one
year
significantli
decreas
averag
compar
patient
mycetoma
infect
durat
refer
group
furthermor
risk
factor
higher
level
ccbi
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
mycetoma
patient
reveal
signific
neg
associ
unit
increment
decreas
level
pgml
p
level
among
patient
durat
mycetoma
infect
one
year
significantli
decreas
pvalu
averag
compar
patient
durat
mycetoma
infect
five
year
refer
group
conclus
studi
indic
neg
associ
level
eumycetoma
mycetoma
infect
high
level
may
neg
impact
diseas
progress
author
summari
mycetoma
progress
chronic
granulomat
fungal
bacteri
infect
may
result
massiv
destruct
subcutan
tissu
muscl
bone
mycetoma
neglect
diseas
endem
mani
tropic
subtrop
area
diseas
treat
properli
eventu
end
amput
advers
medic
health
socioeconom
effect
patient
commun
previou
data
suggest
crucial
role
adapt
immun
host
resist
caus
agent
diseas
progress
recent
identifi
il
cytokin
reveal
import
role
immun
suppress
nevertheless
express
interleukin
patient
mycetoma
yet
investig
therefor
present
casecontrol
studi
aim
determin
level
famili
famili
patient
associ
cytokin
level
patient
demograph
characterist
ccbi
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
result
studi
show
level
consist
posit
correl
differ
diamet
mycetoma
lesion
well
durat
howev
level
consist
neg
correl
differ
diamet
lesion
durat
mycetoma
infect
analysi
risk
factor
higher
circulatori
level
patient
mycetoma
show
signific
neg
associ
cytokin
furthermor
risk
factor
higher
level
patient
mycetoma
reveal
signific
neg
associ
find
uncov
possibl
role
mycetoma
chronic
granulomat
subcutan
inflammatori
diseas
caus
certain
bacteria
actinomycetoma
fungi
eumycetoma
infect
progress
affect
preexist
environ
caus
schistosomiasi
promot
develop
mycetoma
patient
mycetoma
significantli
posit
schistosoma
antibodi
healthi
endem
control
find
suggest
like
respons
antiinflammatoryimmunosuppress
cytokin
could
neg
impact
mycetoma
develop
diseas
progress
polypeptid
two
form
involv
acutephas
respons
account
sever
alter
relat
onset
variou
medic
disord
demonstr
recent
higher
level
cytokin
strongli
associ
surgic
treat
mycetoma
patient
comparison
treat
without
surgeri
known
proinflammatori
cytokin
involv
cell
death
coordin
cytokin
cleav
matur
activ
diseas
sever
murin
aspergillosi
addit
role
innat
immun
play
pivot
role
regul
adapt
immun
induc
regulatori
reg
cell
impair
activ
effector
tcell
respons
knowledg
studi
report
relationship
mycetoma
pathogenesi
far
poorli
understood
howev
recognis
typic
antiinflammatori
cytokin
predomin
mechan
suppress
associ
abil
suppress
cell
tabl
hand
level
cytokin
constitut
neg
correl
tabl
furthermor
level
cytokin
constitut
posit
correl
tabl
howev
level
cytokin
constitut
neg
correl
tabl
tabl
wherea
level
constitut
posit
correl
tabl
ccbi
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
howev
level
constitut
neg
correl
tabl
tabl
tabl
furthermor
circul
level
significantli
decreas
increas
age
group
year
pvalu
year
pvalu
year
pvalu
tabl
interestingli
level
among
mycetoma
patient
show
statist
signific
differ
itraconazol
compar
ketoconazol
p
tabl
tabl
addit
circul
level
show
signific
associ
differ
age
group
tabl
interestingli
treatment
itraconazol
significantli
increas
circul
level
among
mycetoma
patient
compar
treatment
ketoconazol
pvalu
tabl
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
mycetoma
infect
durat
refer
group
investig
need
explor
mechan
contribut
mycetoma
infect
outcom
help
understand
role
cytokin
pathogenesi
mycetoma
may
exploit
potenti
therapeut
target
prevent
mycetoma
diseas
recurr
ccbi
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
tabl
correl
serum
level
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
